Fore Biotherapeutics

Company Overview

Snapshot

Founded in June 2011 by Haim Gil-ad, Fore Biotherapeutics operates with 51–200 employees. The company has raised $153.5M across 7 funding rounds from 14 investors. In August 2023, Fore Biotherapeutics announced a Series D financing round, led by Medicxi.

Business overview

Fore Biotherapeutics is a precision oncology company focused on developing treatments for rare cancers. Leveraging its proprietary functional genomics platform, Foresight, the company identifies and targets unaddressed tumor mutations. This technology elucidates disease biology to match patients with hyper-targeted therapies, serving the pharmaceutical and healthcare industries by accelerating drug discovery and providing tailored treatments.

Strategic signal

In August 2023, Fore Biotherapeutics secured $75M in Series D financing, co-led by Medicxi. This significant capital infusion, alongside a CEO transition, signals strong investor confidence in the company's precision oncology pipeline and strategic direction, positioning it for accelerated clinical development and market expansion.

Company Intelligence Q&A

What was the most recent funding event for Fore Biotherapeutics?

In August 2023, Fore Biotherapeutics announced a Series D financing round, led by Medicxi. This round also coincided with a CEO transition for the company.

When did Fore Biotherapeutics receive FDA Orphan Drug Designation for FORE8394?

In March 2023, FORE Biotherapeutics received FDA Orphan Drug Designation for FORE8394 for the treatment of primary brain and CNS malignancies.

When did Fore Biotherapeutics begin its global Phase 2 trial for FORE8394?

In February 2023, Fore Biotherapeutics announced the first patient had been dosed in its global Phase 2 trial evaluating FORE8394 in BRAF-mutated solid and brain tumors.

When did Fore Biotherapeutics appoint its current CEO?

In April 2022, Fore Biotherapeutics appointed Matthew E. Ros as its Chief Executive Officer.

When did Fore Biotherapeutics receive Fast Track Designation for FORE8394?

In September 2022, Fore Biotherapeutics announced that the FDA granted Fast Track Designation to FORE8394 for the treatment of cancers harboring BRAF Class 1 and Class 2 alterations.